JULY 23, 2021 | EYEWORLD DAILY NEWS | 7
Omeros
7
Cynthia Matossian Cynthia Matossian
Keith Walter Steve Silverstein
Richard Lindstrom
James Loden Bob Osher
Your name here
Denise Visco
Mitch Jackson Mitch Jackson
John Sheppard John Sheppard
Inder Paul Singh
Sheri Rowen Sheri Rowen
John Hovanesian John Hovanesian
Frank Bucci
Cathleen McCabe
™
Keith Walter Denise Visco Inder Paul Singh
™
INDICATIONS AND USAGE
OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is added to ophthalmic irrigating solution used during
cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis
and reducing postoperative ocular pain.
IMPORTANT SAFETY INFORMATION
OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid
derivatives, and other nonsteroidal anti-infl ammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥2% are eye irritation, posterior capsule opacifi cation, increased intraocular
pressure, and anterior chamber infl ammation.
Please see the Full Prescribing Information for OMIDRIA at www.omidria.com/prescribinginformation.
You are encouraged to report Suspected Adverse Reactions to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
References: 1. Omeros survey data on fi le. 2. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017. 3. Al-Hashimi S,
Donaldson K, Davidson R, et al; for ASCRS Refractive Cataract Surgery Subcommittee. Medical and surgical management of the
small pupil during cataract surgery. J Cataract Refract Surg. 2018;44:1032-1041.
The healthcare professionals portrayed in this advertisement are consultants of Omeros Corporation.
These cataract surgeons use OMIDRIA®
(phenylephrine and ketorolac intraocular
solution) 1% / 0.3% for less stress, pure
success in their O.R. day
1
What about you?
OMIDRIA helps your cataract surgery by inhibiting prostaglandin release to block
inflammation and maintain iris tone, preventing miosis and reducing postoperative
pain for your patients.
2,3
Experience less stress in your O.R. day with OMIDRIA.
1
OMEROS®, the OMEROS logo®, OMIDRIA®, and the OMIDRIA logo®
are registered trademarks of Omeros Corporation.
© Omeros Corporation 2021, all rights reserved. US-OM-2100047
™
Eric Donnenfeld
